Cover Image
市場調查報告書

胰臟的轉移性腺癌症:開發中產品分析

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 269899
出版日期 內容資訊 英文 217 Pages
訂單完成後即時交付
價格
Back to Top
胰臟的轉移性腺癌症:開發中產品分析 Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 217 Pages
簡介

所謂轉移性胰臟癌是產生於胰臟,之後轉移到肝臟、肺及骨骼等其他部位類型的癌症。症狀有背部疼痛,體重減輕,食慾衰退,黃疸,尿液暗沈及淺黏土色的糞便等。也可能會出現噁心,嘔吐及全身倦怠感。發病要素有家族病史、吸煙、慢性胰臟炎及糖尿病等。治療方法有外科手術、化療及放射線療法。

本報告提供胰臟的轉移性腺癌症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

胰臟的轉移性腺癌症概要 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • AbbVie Inc.
  • Aduro BioTech, Inc.
  • Array BioPharma Inc.
  • Axcentua Pharmaceuticals AB
  • Berg LLC
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • CTI BioPharma Corp.
  • CytRx Corporation
  • Eleison Pharmaceuticals LLC
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Incyte Corporation
  • Merrimack Pharmaceuticals, Inc.
  • NewLink Genetics Corporation
  • Novartis AG
  • Oncolytics Biotech Inc.
  • Pfizer Inc.
  • Phoenix Biotechnology, Inc.
  • Plexxikon Inc.
  • Sanofi
  • Targovax AS

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • aldoxorubicin hydrochloride
  • AXP-10711
  • BI-853520
  • binimetinib
  • Cellular Immunotherapy for Cancer
  • Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer
  • ceritinib
  • CRS-207
  • glufosfamide
  • GS-5745
  • GSK-2256098
  • ibrutinib
  • INCB-52793
  • indoximod
  • irinotecan hydrochloride
  • LGK-974
  • MesoCART
  • Monoclonal Antibody Conjugate to Target Mesothelin for Oncology
  • napabucasin
  • paclitaxel
  • palbociclib
  • PBI-05204
  • pelareorep
  • plerixafor
  • PLX-7486
  • PRI-724
  • ribociclib
  • SGT-53
  • sonidegib phosphate
  • TG-01
  • tosedostat
  • ubidecarenone
  • ulixertinib
  • Vaccine for Oncology

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8420IDB

Summary

Global Markets Direct's, 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016', provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas
  • The report reviews pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Adenocarcinoma of The Pancreas therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Adenocarcinoma of The Pancreas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Adenocarcinoma of The Pancreas Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview
    • Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis
  • Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies
  • Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies
  • Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes
  • Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Aduro BioTech, Inc.
    • Array BioPharma Inc.
    • Axcentua Pharmaceuticals AB
    • Berg LLC
    • Boehringer Ingelheim GmbH
    • Boston Biomedical, Inc.
    • CTI BioPharma Corp.
    • CytRx Corporation
    • Daiichi Sankyo Company, Limited
    • Eleison Pharmaceuticals LLC
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • Incyte Corporation
    • MabVax Therapeutics Holdings, Inc.
    • Merrimack Pharmaceuticals, Inc.
    • NewLink Genetics Corporation
    • Novartis AG
    • Oncolytics Biotech Inc.
    • Pfizer Inc.
    • Phoenix Biotechnology, Inc.
    • Targovax ASA
  • Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aldoxorubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AXP-10711 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-853520 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • binimetinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceritinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glufosfamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-5745 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2256098 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HuMab-5B1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-52793 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • indoximod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MesoCART - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • napabucasin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nimotuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBI-05204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pelareorep - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-7486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRI-724 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ribociclib succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGT-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sonidegib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tosedostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ubidecarenone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulixertinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metastatic Adenocarcinoma of The Pancreas - Dormant Projects
  • Metastatic Adenocarcinoma of The Pancreas - Discontinued Products
  • Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones
    • Featured News & Press Releases
      • Aug 04, 2016: Merrimack Provides Update on ONIVYDE
      • Jul 21, 2016: Baxalta receives CHMP positive opinion on Onivyde for the treatment of metastatic adenocarcinoma of the pancreas
      • Jun 21, 2016: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
      • May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016
      • Apr 14, 2016: Targovax reports immune response with reduced number of TG01 vaccinations
      • Jan 25, 2016: Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
      • Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission
      • Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016
  • Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by AbbVie Inc, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Array BioPharma Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Berg LLC, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by CTI BioPharma Corp., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by CytRx Corporation, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Pfizer Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Targovax ASA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016
  • Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top